Daiichi Sankyo

News

AZ's Etcamah falls short in first-line breast cancer trial

A week after getting FDA approval for frontline breast cancer treatment, AstraZeneca's Etcamah missed the mark in a trial aiming to expand its label.

News

Enhertu OK ends 10-year EU gap in frontline breast cancer

Enhertu plus Perjeta has become the first new frontline therapy approved for advanced HER2-positive breast cancer in the EU for over a decade.

News

Datroway joins Trodelvy for frontline TNBC in the EU

AstraZeneca and Daiichi Sankyo's Datroway enters the first-line triple-negative breast cancer market in the EU, taking on Gilead's Trodelvy.

Oncology

ASCO 2026: Three ADC approvals in five days, with Ken Keller...

At ASCO 26, Daiichi Sankyo leaders Ken Keller and John Tsai chatted with pharmaphorum about their big year of oncology launches, halfway in.

News

Datroway is first TROP2 drug for frontline breast cancer

AZ and Daiichi's Datroway has been cleared by the FDA as first-line treatment for triple-negative breast cancer patients ineligible for immunotherapy.

News

Manufacturing hangover drives Daiichi Sankyo into the red

Long-term third-party manufacturing contracts and a slower-than-expected rollout of its cancer ADCs have driven Daiichi Sankyo into a net loss.

AZ's Etcamah falls short in first-line breast cancer trial

Enhertu OK ends 10-year EU gap in frontline breast cancer

Datroway joins Trodelvy for frontline TNBC in the EU

ASCO 2026: Three ADC approvals in five days, with Ken Keller...

Datroway is first TROP2 drug for frontline breast cancer

Manufacturing hangover drives Daiichi Sankyo into the red

GSK showcases positive data with lung cancer drugs at WCLC

Discover a new era of healthcare panel engagement: Grounded ...

Daiichi Sankyo

Editor's Picks